• Injection: 250mg, 500mg, 1g

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• 250mg, 500mg & 1g injections 

• Injection: 500/100 (600mg), 1000/200 (1.2g)

• Tablets: 250/125, 500/125
• Oral suspension (sugar-free available): 125/31, 250/62, 400/57

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• 1g and 2g vials
  
  
  
  • Approved as an alternative to flucloxacillin in patients with non-immediate penicillin allergy or in those who cannot tolerate flucloxacillin or alternatives
  
  
  • To be used on the advice of microbiology and ID physicians only.
  
  
  
  

• 1g powder for concentrate for solution for infusion
  
  
  
  • approved for the treatment of infections with gram negative aerobic bacteria in patients with limited treatment options. Only to be used on the advice of mricbiology and ID physicians
  
  
  
  

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
• 200mg tablets
• 100mg in 5ml paediatric suspension: also approved for the prevention of irinotecan induced diarrhoea, specialist use only .

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• Approved for the treatment of hospital acquired pneumonia and other infections on the advice of microbiology/infectious disease physicans.

• Approved for use in multiple antibiotic resistant strains of enterobacteriaceae, pseudomonas and acinetobacters on the advice of microbiology/infectious disease physicians.

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines. 
• Approved for use in primary care (i.e. care homes) to treat patients with conditions such as UTIs and pneumonia, at risk of sepsis in line with local guidance and microbiology input 

• 2.5g injection
• Approved for use only on the advice of Microbiology/Infectious Diseases for the treatment of infections with carbapenemase-producing organisms for which treatment options are very limited, toxic and not particularly effective.

• Imipenem 500 mg,  Cilastatin 500 mg & Relebactam 250 mg powder for solution for infusion
  
  
  
  • Approved for the treatment of multi-resistant gram-negative infections ONLY on the advice of microbiologists
  
  
  
  

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• Meropenem 1 gram / vaborbactam 1 gram. To be used only on advice of microbiology/infectious disease physician

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• To be used in accordance with NHS England Commissioning Policy   

• 50mg and 100mg capsules 


• 100mg/5ml injection   unlicensed
  
  
  
  • approved as sclerosing agent for lymphatic malformations in children
  
  
  
  

• Note: not be prescribed for the treatment of acne in new patients (July 2019). 

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
• Approved for the treatment of non-tuberculous mycobacterial pulmonary diseases caused by Mycobacterium Avium Complex (MAC) that is refractory to current treatment options (adults and post pubescent children) in line with NHSE Specialised Commissioning Policy 

• 80mg in 2ml & 20mg in 2ml IV/IM injections
• 5mg in 1ml intrathecal injection
• bone cement & beads (for use in orthopaedic surgery) unlicensed.

• 500mg tablets
• 1g in 10ml syrup unlicensed.

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
  
  • 80mg in 2ml & 240mg in 6ml injections.
  • 300mg in 4ml (Bramitob®).
  • 300mg in 5ml (Tobi®).
  • TOBI Podhaler.
  
  
• Inhaled preparations to be used for treatment of Cystic Fibrosis in accordance with NHS England Commissioning Policy/NICE Guidance.   

• Approved for
  • For long term therapy in non-cystic fibrosis bronchiectasis usually in patients having > 3 exacerbations per annum with an organism identified as being sensitive to gentamicin.
  • Nebulised therapy for patients on assisted ventilation, patients with tracheostomies and those with persistant bacterial bronchitis 

• Only approved for the treatment of gonorrhoea in adults.

• Injection (for IV infusion): 500mg

• Injection for infusion: 1g vial*

• 500mg powder vial for infusion

• Tablets: 250mg, 500mg
• Capsules: 250mg
• Oral suspension: 200mg/5ml

• 150mg capsules.
• 75mg in 5ml suspension unlicensed

• Injection: 300mg/2ml, 600mg/4ml

• 500mg injection
• approved for the treatment of significant deep soft tissue infections such as joint, discitis and spinal infection, on the advice of infectious disease physicians or microbiology.

• 200mg tablet and 200mg powder for concentrate for solution for infusion
• Approved for thre treatment of bacterial skin and skin structure infections only on the advice of microbiologists/ID physicians

• Tablets: 500 mg

• Approved for
  • Pregnant women infected with Mycoplasma Genitalium (MG) infection that is resistant to macrolides
  • Mycoplasma Genitalium (MG) infection that is resistant to macrolides, quinolones and tetracyclines in both men and women

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• 500mg capsules unlicensed 
• 4g injections 
• 3g sachets: sachets can be initiated in primary care for the treatment of UTIs caused by multi-resistant organisms following advice from microbiology only. Most cost effective option to be used 

• 250mg film coated tablets
• 250mg in 5ml suspension

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• 20mg in 4ml intrathecal injection unlicensed 
• 500mg and 1g injections 

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
  
  • 125mg capsules 

• IV infusion: 600mg/300ml

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• 600mg tablets
• 100mg in 5ml suspension

To be used only on the advice of a Consultant Microbiologist for resistant Gram-positive infections.

Patients must have weekly bloods taken to monitor for haematological side effects if receiving treatment for more than 10 to 14 days. In those receiving treatment for more than 4 weeks a pre-treatment eye assessment is recommended followed by monthly assessments. Patients should be warned to report any visual symptoms promptly (see BNF for CSM warning).

Linezolid is a MAO inhibitor and so potentially life threatening interactions can occur. Check before prescribing.

• 600mg tablets
• 100mg in 5ml suspension

To be used only on the advice of a Consultant Microbiologist for resistant Gram-positive infections.

RED drug for courses greater than 14 days  

Patients must have weekly bloods taken to monitor for haematological side effects if receiving treatment for more than 10 to 14 days. In those receiving treatment for more than 4 weeks a pre-treatment eye assessment is recommended followed by monthly assessments. Patients should be warned to report any visual symptoms promptly (see BNF for CSM warning).

Linezolid is a MAO inhibitor and so potentially life threatening interactions can occur. Check before prescribing.

• 1 million-unit & 2 million-unit vial for nebulisation/intravenous injection
  
  • Nebulised therapy for bronchiectasis 
  • Nebulised therapy for patients on assisted ventilation, patients with tracheostomies and those with persistant bacterial bronchitis 
  • To be used for treatment of Cystic Fibrosis in accordance with NHS England Commissioning Policy/NICE Guidance.
  • Nebulised therapy for CF .
  • Intravenous therapy .
  • Dry powder for inhalation (Colobreath®) .
    
    

• 550mg Tablets: Only approved for use in accordance with NICE guidance. 

• 200mg tablets
• Fidaxomicin 40mg/ml granules for oral suspension
  • Approved for use in the treatment of C. difficile. To be initiated on the recommendation of a consultant microbiologist.

• 480mg in 5ml ampoules for IV infusion

• 480mg tablets, 960mg tablets
• 240mg in 5ml & 480mg in 5ml suspensions.

• 1g injection

• Infectious diseases, microbiology or respiratory advice only Only in patients with MDR-TB intolerant of other medication

• 250mg capsules Infectious diseases
• microbiology or respiratory advice only

• 50mg in 2ml injection

• 50mg & 100mg tablets
• 50mg in 5ml elixir unlicensed

• 150mg & 300mg capsules 
• 100mg in 5ml syrup 
• 600mg vials for IV infusion   

• To be used in accordance with NHS England Commissioning Policy 

• To be used in accordance with NHS England Commissioning Policy 

• 250mg tablets - Unlicensed

• Infectious diseases, microbiology or respiratory advice only

• 50mg and 100mg capsules
  
  • Approved for the treatment of non-tuberculous mycobacterial (NTM) infections, on the advice of microbiology and Infectious Diseases (ID) physicians

• Used in the treatment of leprosy and some skin conditions (e.g. dermatitis herpetiformis, pemphigoid on the advice of dermatologists).

• 200mg & 400mg tablets 
• 200mg in 5ml suspension 
• 500mg & 1g suppositories 

• 50mg in 10ml injection & 500mg in 100ml IV infusion 

• 100mg & 200mg, 400mg intravenous infusions 

• 450mg tablets

• 300mg powder for concentrate for solution for infusion
  
  
• approved for the treatment of acute bacterial skin and skin structure infections where other antibiotics are inappropriate either due to resistant organisms or intolerance/allergy

• 500mg/100ml infusion 

• 240mg/2.4ml nebuliser solution in line with NHS England Commissioning Policy

• IV infusion: 200mg/100ml 

• Tablets: 200mg, 400mg
• For use in the treatment of pelvic inflammatory disease and chlamydia genital tract infections in accordance with local primary care guidelines.

• 250mg & 500mg tablets 

• Note: Liquid presentations of nitrofurantoin are very expensive compared to
  other solid dosage formulation. Please consider whether capsules can be used.

• Approved as second line agent for prophylaxis in patients with recurrent UTI’s who have failed long-term antibiotic prophylaxis, have contraindications to antibiotics or breakthrough infection with resistant organisms.